C3 glomerulopathy: a new classification

Servais, A. et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J. Med. Genet. 44, 193–199 (2007).

Alchi, B. & Jayne, D. Membranoproliferative glomerulonephritis. Pediatr. Nephrol. doi:10.1007/s00467-009-1322–1327.

Habib, R., Gubler, M. C., Loirat, C., Maiz, H. B. & Levy, M. Dense deposit disease: a variant of membranoproliferative glomerulonephritis. Kidney Int. 7, 204–215 (1975).

Walker, P. D., Ferrario, F., Joh, K. & Bonsib, S. M. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod. Pathol. 20, 605–616 (2007).

Levy, M., Gubler, M. C., Sich, M., Beziau, A. & Habib, R. Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (type I MPGN). Clin. Immunol. Immunopa thol. 10, 477–492 (1978).

Lachmann, P. J. The amplification loop of the complement pathways. Adv. Immunol. 104, 115–149 (2009).

Licht, C. & Frémeaux-Bacchi, V. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. Thromb. Haemost. 101, 271–278 (2009).

Montes, T., Tortajada, A., Morgan, B. P., Rodriguez de Cordoba, S. & Harris, C. L. Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B. Proc. Natl Acad. Sci. USA 106, 4366–4371 (2009).

Tortajada, A. et al. The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum. Mol. Genet. 18, 3452–3461 (2009).

Pickering, M. C. & Cook, H. T. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin. Exp. Immuno l. 151, 210–230 (2008).

Jokiranta, T. S. et al. Where next with atypical hemolytic uremic syndrome? Mol. Immunol. 44, 3889–3900 (2007).

Kavanagh, D., Richards, A. & Atkinson, J. Complement regulatory genes and hemolytic uremic syndromes. Annu. Rev. Med. 59, 293–309 (2008).

Loirat, C., Noris, M. & Frémeaux-Bacchi, V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr. Nephrol. 23, 1957–1972 (2008).

Smith, R. J. et al. New approaches to the treatment of dense deposit disease. J. Am. Soc. Nephrol. 18, 2447–2456 (2007).

West, C. D., Witte, D. P. & McAdams, A. J. Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2. Am. J. Kidney Dis. 37, 1120–1130 (2001).

Sethi, S. et al. Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int. 75, 952–960 (2009).

Vallota, E. H., Forristal, J., Spitzer, R. E., Davis, N. C. & West, C. D. Continuing C3 breakdown after bilateral nephrectomy in patients with membrano-proliferative glomerulonephritis. J. Clin. Invest. 50, 552–558 (1971).

Nasr, S. H. et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin. J. Am. Soc. Nephrol. 4, 22–32 (2009).

Appel, G. B. et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J. Am. Soc. Nephrol. 16, 1392–1403 (2005).

Bennett, W. M. et al. Mesangiocapillary glomerulonephritis type II (dense-deposit disease): clinical features of progressive disease. Am. J. Kidney Dis. 13, 469–476 (1989).

Cameron, J. S. et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am. J. Med. 74, 175–192 (1983).

Neary, J. J. et al. Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1. J. Am. Soc. Nephrol. 13, 2052–2057 (2002).

Neary, J., Dorman, A., Campbell, E., Keogan, M. & Conlon, P. Familial membranoproliferative glomerulonephritis type III. Am. J. Kidney Dis. 40, E1 (2002).

Goicoechea de Jorge, E. et al. A mutant complement factor H-related 5 protein is associated with familial C3 glomerulonephritis Mol. Immunol. 46, 2822 (2009).

Roumenina, l. et al. Acquired and hereditary complement dysregulation in patients with C3 glomerulopathy. Mol. Immunol. 46, 2864 (2009).

Trouw, L. A. et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J. Clin. Invest. 114, 679–688 (2004).

Pickering, M. C., Botto, M., Taylor, P. R., Lachmann, P. J. & Walport, M. J. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv. Immunol. 76, 227–324 (2000).

Rose, K. L. et al. Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J. C lin. Invest. 118, 608–618 (2008).

Wagner, E. & Frank, M. M. Therapeutic potential of complement modulation. Nat. Rev. Drug Discov. 9, 43–56 (2010).